Armata Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2,285 shs
Average Volume7,163 shs
Market Capitalization$95.52 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ARMP News and Ratings via Email

Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Armata Pharmaceuticals logo

About Armata Pharmaceuticals

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.94 out of 5 stars

Medical Sector

300th out of 842 stocks

Biological Products, Except Diagnostic Industry

50th out of 103 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Frequently Asked Questions

Is Armata Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Armata Pharmaceuticals stock.
View analyst ratings for Armata Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Armata Pharmaceuticals?

Wall Street analysts have given Armata Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Armata Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Armata Pharmaceuticals' next earnings date?

Armata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Armata Pharmaceuticals

How were Armata Pharmaceuticals' earnings last quarter?

Armata Pharmaceuticals Inc. (NYSEAMERICAN:ARMP) issued its earnings results on Wednesday, May, 12th. The company reported ($0.27) EPS for the quarter, topping the Zacks' consensus estimate of ($0.32) by $0.05. The firm had revenue of $1.07 million for the quarter. Armata Pharmaceuticals had a negative trailing twelve-month return on equity of 84.38% and a negative net margin of 1,196.29%.
View Armata Pharmaceuticals' earnings history

What price target have analysts set for ARMP?

2 equities research analysts have issued 1 year price objectives for Armata Pharmaceuticals' stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate Armata Pharmaceuticals' stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 95.8% from the stock's current price.
View analysts' price targets for Armata Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Armata Pharmaceuticals' key executives?

Armata Pharmaceuticals' management team includes the following people:
  • Mr. Todd R. Patrick, CEO & Director (Age 58, Pay $773.25k)
  • Dr. Brian Varnum, Pres & Chief Devel. Officer (Age 61, Pay $558.25k)
  • Mr. Steven R. Martin, Sr. VP & CFO (Age 60, Pay $490k)
  • Dr. Wenyuan Shi, Co-Founder & Founding Scientist
  • Mr. Duane Alfred Morris BA, VP of Operations (Age 71)

Who are some of Armata Pharmaceuticals' key competitors?

What other stocks do shareholders of Armata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), (ALT), CRISPR Therapeutics (CRSP), Pfizer (PFE), Micron Technology (MU), Aduro Biotech (ADRO), Occidental Petroleum (OXY) and Gilead Sciences (GILD).

What is Armata Pharmaceuticals' stock symbol?

Armata Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ARMP."

How do I buy shares of Armata Pharmaceuticals?

Shares of ARMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Armata Pharmaceuticals' stock price today?

One share of ARMP stock can currently be purchased for approximately $3.83.

How much money does Armata Pharmaceuticals make?

Armata Pharmaceuticals has a market capitalization of $95.52 million and generates $820,000.00 in revenue each year. The company earns $-22,180,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does Armata Pharmaceuticals have?

Armata Pharmaceuticals employs 59 workers across the globe.

What is Armata Pharmaceuticals' official website?

The official website for Armata Pharmaceuticals is www.armatapharma.com.

Where are Armata Pharmaceuticals' headquarters?

Armata Pharmaceuticals is headquartered at 4503 GLENCOE AVENUE, MARINA DEL REY CA, 90292.

How can I contact Armata Pharmaceuticals?

Armata Pharmaceuticals' mailing address is 4503 GLENCOE AVENUE, MARINA DEL REY CA, 90292. The company can be reached via phone at (310) 655-2928 or via email at [email protected]

This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.